Stable retrovirus and methods of use

Details Stable retrovirus and methods of use Stable retrovirus and methods of use

2007-02-21

2009-02-03

Mosher, Mary E (Department: 1648)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S183000, C435S212000, C435S219000, C435S005000, C930S010000, C930S221000

Reexamination Certificate

active

07485446

ABSTRACT:
The present invention is a mutant retroviral protease which confers an increase in retroviral stability. Retroviruses expressing the instant mutant retroviral protease exhibit at least a 2-fold increase in infectivity half-life as compared to wild-type retrovirus. Unexpectedly, a Gly119Glu mutation in the protease enhances retroviral stability in the presence of various wild-type envelope proteins including wild-type amphotropic, ecotropic and 10A1 murine leukemia viruses. The improved stability of the mutant retrovirus leads to more facile virus production and enhanced infection efficiency.

REFERENCES:
patent: 6096548 (2000-08-01), Stemmer
patent: 6596539 (2003-07-01), Stemmer et al.
patent: 6713279 (2004-03-01), Short
patent: 6846628 (2005-01-01), Wohlstadter
Wlodawer, et. al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989; 245(4918):616-621.
Masso & Vaisman. Comprehensive mutagenesis of HIV-1 protease: a computational geometry approach. Biochem Biophys Res Comm. 2003; 305:322-326.
Kim, et al. Functional Correlates of Insertion Mutations in the Protease Gene of Human Immunodeficiency Virus Type 1 Isolates from Patients. J Virol. 2001; 75(22):11227-11233.
Hayakawa, et al. Requirement of N- and C-terminal regions for enzymatic activitty of human T-cell leukemia virus type I protease. Eur. J. Biochem. 1992; 206:919-925.
Yahi, et al. Use of Drug Resistance Sequence Data for the Systematic Detection of Non-B Human Immunodeficiency Virus Type 1 (HIV-1) Subtypes: How to Creat a Sentinel Site for Monitoring the Genetic Diversity of HIV-1 at a Country Scale. J Inf Dis. 2001; 183:1311-1316.
Fonjungo, et al. Human Immunodeficiency Virus Type 1 Group M Protease in Cameroon: Genetic Diversity and Protease Inhibitor Mutational Features. J Clin Microbiol. 2002; 40(3): 837-845.
Nath, et al. The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol. 2000; 8(9):426-431.
Cohen, J. Promising AIDS Vaccine's Failure Leaves Field Reeling. Science. 2007; 318:28-29.
Layne, et al. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology. 1992; 189(2) 695-714. Abstract Only.
Fu, et al. Effects of Gag Mutation an Processing on Retroviral Dimeric RNA Maturation. J Virol. 2006; 80(3):1242-1249.
Loeb, et al. Complete mutagenesis of the HIV-1 protease. Nature. 1989; 340:397-400.
Arnold, Frances H., “Design by Directed Evolution”, Acc. Chem. Res. 1998 37:125-131.
Menendez-Arias et al., “Mutational Analysis of the Substrate Binding Pocket of Murine Leukemia Virus Protease and Comparison with Human Immunodeficiency Virus Proteases”, J. Biol. Chem. 1995 270(49):29162-29168.
Patnaik et al., “Genome shuffling of Lactobacillus for improved acid tolerance”, Nature Biotechnology 2002 20:707-712.
Stemmer, Willem P.C., “Rapid evolution of a protein in vitro by DNA shuffling”, Nature 1994 370:389-391.
Zhang et al., “Genome shuffling leads to rapid phenotypic improvement in bacteria”, Natur5e 2002 415:644-646.

Affiliated with

Also associated with

Rating

Stable retrovirus and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stable retrovirus and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable retrovirus and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4064622